<DOC>
	<DOCNO>NCT00161122</DOCNO>
	<brief_summary>The PRIMAKid trial general practice base double-blind randomized placebo-controlled trial effectiveness cost combine influenza pneumococcal vaccination pre-school child recurrent respiratory tract infection . A target number 660 child age 18-72 month history two general practitioner attend episode RTI , include . Exclusion criterion diseases accompanied high risk recurrent RTI condition chronically treat corticosteroid . Over period 7 22 month follow-up , number febrile RTI-episodes primary outcome assess , secondary outcome severity length febrile RTI-episodes , medical visit / intervention , health-related quality life productivity loss parent .</brief_summary>
	<brief_title>Prevention Respiratory Infections MAnagement Among Children ( PRIMAKid )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Age 1872 month A history two episodes general practitioner attend RTIs No intention move within 12 month another region Provision inform consent Good mastering Dutch language Absence chronic disease asthma treat corticosteroid highrisk disease ( palatoschisis , Down syndrome , cystic fibrosis , etc . ) No previous influenza vaccination pneumococcal vaccination Hepatitis B vaccination No hypersensitivity egg and/or antibiotic , and/or serious history serious adverse event vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>72 Months</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>